Gene expression profiling predicts clinical outcome of breast cancer (original) (raw)

Nature volume 415, pages 530–536 (2002)Cite this article

Abstract

Breast cancer patients with the same stage of disease can have markedly different treatment responses and overall outcome. The strongest predictors for metastases (for example, lymph node status and histological grade) fail to classify accurately breast tumours according to their clinical behaviour1,2,3. Chemotherapy or hormonal therapy reduces the risk of distant metastases by approximately one-third; however, 70–80% of patients receiving this treatment would have survived without it4,5. None of the signatures of breast cancer gene expression reported to date6,7,8,9,10,11,12 allow for patient-tailored therapy strategies. Here we used DNA microarray analysis on primary breast tumours of 117 young patients, and applied supervised classification to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis (lymph node negative). In addition, we established a signature that identifies tumours of BRCA1 carriers. The poor prognosis signature consists of genes regulating cell cycle, invasion, metastasis and angiogenesis. This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. McGuire, W. L. Breast cancer prognostic factors: evaluation guidelines. J. Natl Cancer Inst. 83, 154–155 (1991).
    Article CAS Google Scholar
  2. Goldhirsch, A., Glick, J. H., Gelber, R. D. & Senn, H. J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J. Natl Cancer Inst. 90, 1601–1608 (1998).
    Article CAS Google Scholar
  3. Eifel, P. et al. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl Cancer Inst. 93, 979–989 (2001).
    Article CAS Google Scholar
  4. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930–942 (1998).
    Article Google Scholar
  5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451–1467 (1998).
    Article Google Scholar
  6. Perou, C. M. et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl Acad. Sci. USA 96, 9212–9217 (1999).
    Article ADS CAS Google Scholar
  7. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
    Article ADS CAS Google Scholar
  8. Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979–5984 (2001).
    CAS PubMed Google Scholar
  9. Martin, K. J. et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 60, 2232–2238 (2000).
    CAS PubMed Google Scholar
  10. Zajchowski, D. A. et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 61, 5168–5178 (2001).
    CAS PubMed Google Scholar
  11. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
    Article ADS CAS Google Scholar
  12. West, M. et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98, 11462–11467 (2001).
    Article ADS CAS Google Scholar
  13. Hughes, T. R. et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nature Biotechnol. 19, 342–347 (2001).
    Article CAS Google Scholar
  14. Roberts, C. J. et al. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. Science 287, 873–880 (2000).
    Article ADS CAS Google Scholar
  15. Lakhani, S. R. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90, 1138–1145 (1998).
    Article CAS Google Scholar
  16. Brenton, J. D., Aparicio, S. A. & Caldas, C. Molecular profiling of breast cancer: portraits but not physiognomy. Breast Cancer Res. 3, 77–80 (2001).
    Article CAS Google Scholar
  17. Khan, J. et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Naure Med. 7, 673–679 (2001).
    CAS Google Scholar
  18. He, Y. D. & Friend, S. H. Microarrays—the 21st century divining rod? Nature Med. 7, 658–659 (2001).
    Article CAS Google Scholar
  19. Bieche, I. et al. Genetic alterations in breast cancer. Genes Chromosomes Cancer 14, 227–251 (1995).
    Article CAS Google Scholar
  20. Steeg, P. S. & Zhou, Q. Cyclins and breast cancer. Breast Cancer Res. Treat. 52, 17–28 (1998).
    Article CAS Google Scholar
  21. Janicke, F. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl Cancer Inst. 93, 913–920 (2001).
    Article CAS Google Scholar
  22. van Diest, P. J. et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am. J. Pathol. 150, 705–711 (1997).
    CAS PubMed PubMed Central Google Scholar
  23. Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H. & Boyer, T. G. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl Acad. Sci. USA 98, 9587–9592 (2001).
    Article ADS CAS Google Scholar
  24. Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92, 564–569 (2000).
    Article CAS Google Scholar
  25. Chapman, M. S. & Verma, I. M. Transcriptional activation by BRCA1. Nature 382, 678–679 (1996).
    Article ADS CAS Google Scholar
  26. Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548 (2001).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank D. Atsma and D. Majoor for assistance with the histological analyses and the preparation of tumour RNA; T. van der Velde, W. van Waardenburg and O. Dalesio for medical record data extraction; D. Slade, J. McDonald, J. Koch, T. Erkkila, M. Parrish and others at Rosetta's High Throughput Gene Expression Profiling Facility for microarray experiments; R. Stoughton, F. van Leeuwen, M. Rookus, P. Nederlof, F. Hogervorst and D. Voskuil for suggestions; and A. Berns, L. Hartwell, J. Radich and S. Rodenhuis for support and reading of the manuscript. This work was supported by a grant from the Center for Biomedical Genetics.

Author information

Author notes

  1. Laura J. van 't Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Mao Mao, Matthew J. Marton, George J. Schreiber, Chris Roberts, Peter S. Linsley and Stephen H. Friend: These authors contributed equally to this work

Authors and Affiliations

  1. Divisions of Diagnostic Oncology, Radiotherapy and Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, 121 Plesmanlaan, Amsterdam, 1066 CX, The Netherlands
    Laura J. van 't Veer, Marc J. van de Vijver, Augustinus A. M. Hart, Hans L. Peterse, Karin van der Kooy, Anke T. Witteveen, Ron M. Kerkhoven & René Bernards
  2. Rosetta Inpharmatics, 12040 115th Avenue NE, Kirkland, 98034, Washington, USA
    Hongyue Dai, Yudong D. He, Mao Mao, Matthew J. Marton, George J. Schreiber, Chris Roberts, Peter S. Linsley & Stephen H. Friend

Authors

  1. Laura J. van 't Veer
    You can also search for this author inPubMed Google Scholar
  2. Hongyue Dai
    You can also search for this author inPubMed Google Scholar
  3. Marc J. van de Vijver
    You can also search for this author inPubMed Google Scholar
  4. Yudong D. He
    You can also search for this author inPubMed Google Scholar
  5. Augustinus A. M. Hart
    You can also search for this author inPubMed Google Scholar
  6. Mao Mao
    You can also search for this author inPubMed Google Scholar
  7. Hans L. Peterse
    You can also search for this author inPubMed Google Scholar
  8. Karin van der Kooy
    You can also search for this author inPubMed Google Scholar
  9. Matthew J. Marton
    You can also search for this author inPubMed Google Scholar
  10. Anke T. Witteveen
    You can also search for this author inPubMed Google Scholar
  11. George J. Schreiber
    You can also search for this author inPubMed Google Scholar
  12. Ron M. Kerkhoven
    You can also search for this author inPubMed Google Scholar
  13. Chris Roberts
    You can also search for this author inPubMed Google Scholar
  14. Peter S. Linsley
    You can also search for this author inPubMed Google Scholar
  15. René Bernards
    You can also search for this author inPubMed Google Scholar
  16. Stephen H. Friend
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toStephen H. Friend.

Ethics declarations

Competing interests

S.H.F. is the Vice President of the MRC Merck Research Laboratories.

Supplementary information

Rights and permissions

About this article

Cite this article

van 't Veer, L., Dai, H., van de Vijver, M. et al. Gene expression profiling predicts clinical outcome of breast cancer.Nature 415, 530–536 (2002). https://doi.org/10.1038/415530a

Download citation

Associated content